OKYO Pharma Ltd, which is developing a treatment for dry eye disease and ocular pain, has announced plans to list its stock in the US.
The company said it hasn’t yet decided the number of American depositary shares it will sell, their price or the exact date of the Nasdaq IPO.
Plexus Holding PLC has suspended dealings with its Russian licensee partner Gusar due to the situation in Ukraine.
Gusar supplies Plexus’ wellhead equipment into Russia and the CIS and although the suspension is not expected to have a material impact on trading this year to June 2022 there will be a cash flow impact from £650,000 outstanding in royalties.
Mosman Oil and Gas Ltd (AIM:MSMN) told investors that its 23%-owned Winters-2 well, in east Texas, has produced at an initial rate of 105 barrels oil equivalent per day (545,000 cubic feet).
New production from Winters-2 is expected to add significantly to the average daily gross production which was 164 boepd in the December 2021 quarter, Mosman noted.
Zephyr Energy Plc told investors it expects to receive the new competent persons report (CPR) for the Paradox project, in Utah, in “the coming weeks”.
The company, in a statement, noted that because of the large scope of the CPR and a significant increase in activity in the North American oil and gas sector, there has been a slight delay to the report.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received a unanimous recommendation from an independent safety committee to proceed to cohort four of a Phase I intravenous (IV) clinical trial of RECCE® 327 - the only clinical-stage new class of antibiotic in the world being developed for sepsis.
The study is evaluating the safety and pharmacokinetics of R327 in 7-10 healthy subjects per dose, across eight sequential dosing cohorts of 50-16,000mg.
Challenger Energy Group PLC (AIM:CEG, OTC:BSHPF) updated on its ongoing restructuring process, following its EGM last week, with a statement detailing a previously announced issue of equity, board changes, and broker appointment.
The manager of Seraphim Space Investment Trust PLC (LSE:SSIT) the world’s first listed Space Tech Fund announced that it has appointed a new chief operating officer. Seraphim Space (Manager) LLP said Sarah Shackleton, partner of Development Partners International, will report to chief executive Mark Boggett and will be a member of the advisory board, all effective immediately.
Altus Strategies PLC (AIM:ALS, TSX-V:ALTS, OTCQX:ALTUF) told investors that it has appointed Gérard De Hert as a non-executive director, effective immediately. De Hert is managing director (technical services) at La Mancha Holding and his appointment is in accordance with the terms of the strategic investment agreement approved by shareholders last month.
Allergy Therapeutics PLC (AIM:AGY) said chief executive Manuel Llobet, chief financial officer Nick Wykeman, and head of business innovation Alan Bullimore will provide a live presentation relating to the group's interim results on the Investor Meet Company platform on Thursday 10 March 2022 at 10:30am GMT.
Love Hemp Group PLC (AQSE:LIFE, OTCQB:WRHLF) announced late on Friday that it received a letter from a group of shareholders owning 9.6% of the total paid-up capital of the company, that requests the convening of an emergnecy shareholder meeting to consider and potentially propose the following resolutions: the removal of chairman Andrew Male, the reduction of all salaries by 75%, the launching of reviews into strategy and the company's financial history, as well as demanding that the company becomes self-sufficient based on its current income. The board unanimously recommended shareholders vote against all of the resolutions. The general meeting will be held at 11am on 1 April 2022 at Hill Dickinson, 20 Primrose Street, London, EC2A 2EW.